drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
An intravenous bispecific, bivalent T-cell–engaging antibody that binds CD3 on T cells and the MAGE-A4 peptide presented by HLA-A*02:01 on tumor cells to redirect T-cell cytotoxicity.
nci_thesaurus_concept_id
C206172
nci_thesaurus_preferred_term
MAGE-A4-specific T-cell Engager CDR404
nci_thesaurus_definition
A bispecific T-cell engaging antibody directed against the human leukocyte antigen (HLA)-A2-restricted tumor-associated antigen (TAA) human melanoma-associated antigen A4 (MAGE-A4) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon intravenous administration of the MAGE-A4-specific T-cell engager (TCE) CDR404, the anti-MAGE-A4 moiety targets and binds to MAGE-A4 presented on HLA-A2 on tumor cells and the anti-CD3 moiety binds to CD3- expressing cytotoxic T-lymphocytes (CTLs). This selectively cross-links tumor cells and T-lymphocytes and results in a CTL-mediated death of MAGE-A4-expressing tumor cells. MAGE-A4 is overexpressed by a variety of cancer cell types.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
An intravenous bispecific, bivalent antibody that binds CD3 on T cells and the MAGE-A4 peptide presented by HLA-A*02:01 on tumor cells, cross-linking T cells to cancer cells. This engagement activates TCR/CD3 signaling, induces cytokine release, and redirects cytotoxic T-cell killing of MAGE-A4–expressing tumor cells.
drug_name
CDR404
nct_id_drug_ref
NCT06402201